Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Apremilast in Healthy Korean Males
NCT02802735Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apremilast in psoriasis and psoriatic arthritis (PsA) (5 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration at Day 14, Time to Maximum Observed Plasma Concentration at Day 14 and 7 more. Started Jun 2016; status: completed.
02
Drugs
apremilast
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02802735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802735.